AKT pathway
Showing 1 - 25 of 3,091
Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation Trial in Shanghai (Everolimus, Investigator's Choice of
Not yet recruiting
- Triple Negative Breast Cancer
- +2 more
- Everolimus
- Investigator's Choice of Chemotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 25, 2023
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders Trial (ARQ 092)
No longer available
- Proteus Syndrome
- +2 more
- ARQ 092
- (no location specified)
Jul 31, 2021
Everolimus-containing Chemotherapy in HER2- mBC PI3K/AKT/mTOR
Completed
- Breast Cancer
- +2 more
- No intervention, it was a retrospective study.
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Sep 13, 2021
Breast Cancer Trial in Beijing (Inetetamab, Rapamycin, Pyrotinib)
Not yet recruiting
- Breast Cancer
- Inetetamab
- +3 more
-
Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Jan 31, 2021
Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced
Recruiting
- Head and Neck Carcinoma of Unknown Primary
- +24 more
- Cisplatin
- +2 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Aug 6, 2022
Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
Not yet recruiting
- PIK3CA-related Overgrowth Spectrum
- +8 more
- national registry
-
Paris, FranceTranslational medicine and Targeted therapies unit, Hôpital Neck
Sep 28, 2022
Study of Proteus Syndrome and Related Congenital Disorders
Recruiting
- Proteus Syndrome
- PIK3CA Related Overgrowth Spectrum
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 27, 2023
Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)
Recruiting
- Breast Neoplasm
- +4 more
- PIK3CA inhibitor
- +12 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023
Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma Trial in United States
Not yet recruiting
- Esophageal Adenocarcinoma
- +2 more
-
Palo Alto, California
- +5 more
Jan 12, 2023
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)
Recruiting
- HER2-negative Breast Cancer
- +3 more
-
Houston, TexasHouston Methodist Neal Cancer Center
Jan 12, 2023
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Canada, United
Recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +5 more
Jan 7, 2023
Klotho _ LRP-6 _ Gastric Adenocarcinoma
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- Prognostic study
- (no location specified)
Jan 29, 2023
Soft-tissue Sarcoma Trial in Philadelphia (TAK-228)
Terminated
- Soft-tissue Sarcoma
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Sep 19, 2022
Breast Cancer Trial (GSK3326595)
Completed
- Breast Cancer
-
London, Ontario, CanadaSt. Joseph's Health Care London
Oct 24, 2022
Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or
Recruiting
- Triple-negative Breast Cancer
- Pyrotinib with Capecitabine
- +6 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2022
High-Risk Prostate Cancer Trial in Portland (Capivasertib, abiraterone acetate)
Not yet recruiting
- High-Risk Prostate Cancer
- Capivasertib
- abiraterone acetate
-
Portland, OregonVA Portland Health Care System, Portland, OR
Jan 17, 2023
Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +23 more
- Biospecimen Collection
- +2 more
-
Los Angeles, California
- +1 more
Jul 7, 2022
Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma Trial in Dallas
Recruiting
- Esophagus Adenocarcinoma
- +2 more
-
Dallas, TexasDallas VA Medical Center
Nov 2, 2021
Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in United States (Everolimus, Nelarabine, Cyclophosphamide)
Recruiting
- Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Everolimus
- +3 more
-
Atlanta, Georgia
- +3 more
Aug 18, 2022
Barrett Oesophagitis With Dysplasia Trial in Kansas City (Itraconazole in capsule form, Itraconazole in solution form)
Recruiting
- Barrett Oesophagitis With Dysplasia
- Itraconazole in capsule form
- Itraconazole in solution form
-
Kansas City, KansasUniversity of Kansas Medical Center
Nov 1, 2022
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma
Recruiting
- Fallopian Tube Endometrioid Adenocarcinoma
- +17 more
- Biopsy
- +3 more
-
Augusta, Georgia
- +4 more
Jan 25, 2023
Gallbladder Cancer Trial in Varanasi (Next generation sequencing)
Recruiting
- Gallbladder Cancer
- Next generation sequencing
-
Varanasi, UP, IndiaBanaras Hindu University
Jun 2, 2022
